BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16110045)

  • 1. Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.
    Bohnstedt BN; Kronenberger WG; Dunn DW; Giauque AL; Wood EA; Rembusch ME; Lafata D
    J Atten Disord; 2005 May; 8(4):153-9. PubMed ID: 16110045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
    Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
    Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reliability and validity of self- and investigator ratings of ADHD in adults.
    Adler LA; Faraone SV; Spencer TJ; Michelson D; Reimherr FW; Glatt SJ; Marchant BK; Biederman J
    J Atten Disord; 2008 May; 11(6):711-9. PubMed ID: 18025250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parent ratings of school behaviour in children at risk of attention deficit/hyperactivity disorder.
    Sayal K; Taylor E
    Acta Psychiatr Scand; 2005 Jun; 111(6):460-5. PubMed ID: 15877713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
    Buitelaar JK; Wilens TE; Zhang S; Ning Y; Feldman PD
    J Child Psychol Psychiatry; 2009 Mar; 50(3):335-42. PubMed ID: 19309330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Australian parent and teacher ratings of the DSM-IV ADHD symptoms: differential symptom functioning and parent-teacher agreement and differences.
    Gomez R
    J Atten Disord; 2007 Jul; 11(1):17-27. PubMed ID: 17606769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can parent reports serve as a proxy for teacher ratings in medication management of attention-deficit hyperactivity disorder?
    Lavigne JV; Dulcan MK; LeBailly SA; Binns HJ
    J Dev Behav Pediatr; 2012 May; 33(4):336-42. PubMed ID: 22371012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parents report more ADHD symptoms than do teachers in children with epilepsy.
    Sherman EM; Brooks BL; Akdag S; Connolly MB; Wiebe S
    Epilepsy Behav; 2010 Nov; 19(3):428-35. PubMed ID: 20926354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    ; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.